Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights

Ivan Rodriguez, Thomas Norman,Jana Guenther, Kimberly Smart, Andrew Kwong,Jesse Berry, Gino K. In,Scott Worswick

CLINICAL AND EXPERIMENTAL DERMATOLOGY(2024)

引用 0|浏览2
暂无评分
摘要
Tebentafusp, recently approved by the FDA as an immunotherapy agent, has shown great promise in improving outcomes for metastatic uveal melanoma. In this case series, we present six patients treated with tebentafusp at our institution, focusing on the associated cutaneous adverse reactions and their management. A better understanding of the cutaneous adverse reactions associated with tebentafusp is important because, given its promising treatment outcomes, the use of tebentafusp will likely become more widespread. This study highlights the range of possible outcomes and effective treatment regimens for mild-to-severe cutaneous reactions, ensuring that patients can continue tebentafusp treatment without interruption in most cases.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要